PHARMACY

Mylan launches authorized generic Ampyra tablets
The product had a market value of approximately $553 million for the 12 months ended June 30, according to IQVIA.
Upsher-Smith builds brand-like support around Vigadrone
With the launch of Vigadrone, its generic of Sabril — a first-line treatment for infantile spasms in infants with tuberous sclerosis complex — Upsher-Smith is offering an enhanced level of service around the drug.

Dana Mariani joins AAM as policy director

The Association for Accessible Medicines is welcoming Dana Mariani, formerly from Guidehouse, to its policy and strategic alliances team.
Genoa Healthcare's pharmacy debuts in California

Genoa Healthcare, which operates more than 425 pharmacies in behavioral health centers, is opening its first pharmacy in California.
NCPA backs Senate's passage of Patient Right to Know Drug Prices Act

The National Community Pharmacists Association applauded the Senate for passage of S. 2554, the Patient Right to Know Drug Prices Act, saying the legislation will prohibit "gag clauses" in private health plans.
NACDS applauds Senate passage of bill to prohibit ‘gag clauses’

NACDS praised The Patient Right to Know Drug Prices Act (S. 2554), which is part of the effort to empower pharmacists to help patients lower out-of-pocket drug costs.
DSNTV: Welton shares how Elsevier simplifies drug database updates

Drug Store News sat down with Christie Welton, clinical executive at Elsevier, who discussed the company's role in helping simplify the time-consuming obstacle of drug database updates.
Schmitz joins PQA in communications role

Richard Schmitz, a former healthcare public affairs executive at PR firm Golin, is joining PQA as senior director of communication.
FDA approves opioid analgesic risk evaluation, mitigation strategy

The Food and Drug Administration has approved an opioid analgesic risk and evaluation and mitigation strategy as part of a broader set of measures to address the opioid crisis.
Teva's Ajovy for migraine gets FDA green light

The Food and Drug Administration approved Teva Pharmaceutical's Ajovy, which is indicated for the preventive treatment of migraine in adults.